Fundamental studies for elucidating the pathogenesis of transfusion-related acute lung injury - Elucidation of the CTL2 intermolecular network -.

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07361
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: The University of Tokyo
• Principal Investigator: OKAZAKI HITOSHI 東京大学, 医学部附属病院, 教授 (80261973)
• Co-Investigator(Kenkyū-buntansha): 池田 敏之 東京大学, 医学部附属病院, 講師 (80322759) ; 三島 由祐子 杏林大学, 保健学部, 講師 (90815771)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 輸血関連急性肺障害

Outline of Final Research Achievements

Transfusion-related acute lung injury (TRALI) is one of the most serious and potentially fatal adverse reactions of transfusion. The in vivo mechanism of HNA3a/CTL2 signaling has not yet been elucidated, and elucidation of this mechanism in a cell-based system is essential to the understanding of the pathogenesis of TRALI. We sought to elucidate the mechanism of HNA3a/CTL2 signaling in cells, which may lead to a specific treatment for TRALI.

Translated with DeepL.com (free version)

Free Research Field

輸血医学

Academic Significance and Societal Importance of the Research Achievements

輸血関連急性肺障害（TRALI）はその機序が未だ未解明であり、特異的治療が判明していない。非感染性もしくは非溶血性輸血副反応の中でも致死的になりうるTRALIの治療に結びつく機序の解明は輸血の安全性に大きく寄与する。